BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Pandemic Highlights Opportunities, Challenges for Exosomes and Related Cell Therapies

  New therapeutic modalities always face an uphill climb, but the urgency of COVID-19 may have opened the door for two related ones: cell therapies and exosomes.

  August 10, 2021

   · 

  7 min read

   · 

  Mark Zipkin
• 

  Drug Development

  COVID-19 Vaccines Expiring in Wealthy Nations as Developing World Struggles

  In India, only 8.3% of the population is fully vaccinated, while Sudan, Myanmar, and Ethiopia all have blank spaces beside their names in that category.

  August 10, 2021

   · 

  5 min read

   · 

  Heather McKenzie
• 

  Fecal Transplants Could Be New Tool in Fight Against Age-Related Decline

  Recent animal research reported in Nature Aging on Monday suggests fecal transplants may actually reverse the signs of brain aging.

  August 10, 2021

   · 

  3 min read

   · 

  Brandon May
• 

  Pharm Country

  Fera Pharma Pounces on Abandoned Pfizer Pediatric Glaucoma Drug

  Pfizer has made a deal with the small Locust Valley, New York-based company to manufacture and market the drug.

  August 10, 2021

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Gilead Joins Growing List of Biopharma Companies Mandating COVID-19 Vaccination

  As the Delta variant rages on and COVID-19 vaccines move closer to receiving full regulatory approval, many companies across the U.S. and abroad are beginning to mandate their employees get the jab or get the boot.

  August 10, 2021

   · 

  2 min read

   · 

  Brandon May
• 

  Business

  BioNTech’s Bottom Line Significantly Boosted by COVID-19 Vaccine Success

  On Monday, BioNTech announced revenues of €5.308 billion (about $6.2 billion) for the quarter.

  August 10, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  GentiBio Nets $157 Million to Restore Immune Tolerance with Tregs

  Inflammation is an important protective mechanism if it can be controlled. This is a key component of Genti’s engineering and the secret to the potency of its Tregs.

  August 10, 2021

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Business

  BioLife Solutions Strengthens Gene Therapy Capabilities with $24 Million Acquisition

  BioLife will obtain all of the outstanding shares of Sexton that it doesn’t already own for $24 million in consideration for 506,382 newly issued shares of BioLife common stock.

  August 10, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Deals

  mRNA Disruptor Goes Public in $1.5 Billion SPAC Deal

  Messenger RNA has become the life sciences hero of the decade. The lynchpin in the fight against COVID-19, companies are taking mRNA technology to new heights.

  August 10, 2021

   · 

  2 min read

   · 

  Kate Goodwin
• 

  Business

  Santen, Sydnexis Unite to Vanquish Childhood Myopia

  Global biopharmaceutical firms Santen SA and Sydnexis have entered an exclusive licensing deal for a drug formulation that aims to treat progressive myopia.

  August 10, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN